intern
societi
antivir
research
isar
organ
sponsor
annual
intern
meet
intern
confer
antivir
research
icar
annual
icar
held
baltimor
md
usa
may
goal
meet
foster
nurtur
progress
antivir
research
acceler
develop
new
drug
vaccin
help
prevent
treat
mani
viral
diseas
affect
human
anim
previou
year
icar
provid
collegi
environ
recent
advanc
antivir
research
develop
well
histor
perspect
current
situat
analys
worldwid
landscap
viral
diseas
therapi
present
discuss
previou
year
andrei
et
al
bray
et
al
vere
hodg
follow
page
provid
overview
meet
isar
award
one
highlight
meet
year
isar
bestow
fourthev
award
outstand
contribut
societi
mark
prichard
sinc
pass
away
mani
us
use
mark
softwar
seri
analyz
drugdrug
interact
fifthev
isar
award
excel
grant
dr
robert
gallo
discuss
challeng
discoveri
htlv
impact
discoveri
later
discoveri
hiv
current
challeng
pose
htlv
also
introduc
global
viru
network
gertrud
elion
memori
awarde
david
evan
discuss
challeng
opportun
develop
antivir
virus
current
infect
human
antoni
memori
awarde
richard
mackman
present
lectur
develop
activ
remdesivir
ongo
clinic
test
ebola
viru
year
william
prusoff
young
investig
awarde
marnix
van
loock
dissert
dengu
viru
develop
antidengu
drug
pharmaceut
perspect
second
women
scienc
awarde
grace
zhou
gave
excel
perspect
woman
success
career
academi
industri
usa
china
keynot
address
deliv
dian
griffin
spoke
measl
viru
persist
immun
lectur
partli
focus
requir
high
vaccin
coverag
curtail
measl
epidemiolog
differ
challeng
achiev
coverag
http
receiv
june
accept
juli
develop
less
develop
part
world
icar
four
symposia
focus
influenza
emerg
virus
retrovirus
medicin
chemistri
two
session
new
antivir
research
cover
rang
topic
new
challeng
progress
antivir
research
develop
short
talk
organ
session
dedic
specif
virus
diseas
dna
virus
respiratori
hepatotrop
virus
area
medicin
chemistri
poster
present
expand
area
antivir
research
develop
previou
year
symposia
session
short
talk
shotgun
talk
poster
present
altogeth
gave
excel
background
updat
challeng
pose
virus
virolog
chemic
aspect
antivir
drug
discoveri
develop
academia
industri
health
care
nation
intern
government
nonforprofit
organ
year
icar
thu
continu
reinforc
one
major
strength
societi
bring
togeth
peopl
work
area
antivir
discoveri
develop
differ
set
also
highlight
intern
presenc
mani
talk
research
usa
europ
china
japan
australia
india
singapor
south
america
part
world
program
icar
access
http
wwwisaricarcom
follow
page
provid
gener
overview
meet
topic
present
discuss
icar
excel
opportun
peopl
stage
career
varieti
profession
set
usual
mix
attende
academia
industri
govern
nongovernment
nation
intern
organ
set
continu
facilit
prompt
discoveri
develop
much
need
antivir
treatment
isar
award
outstand
contribut
societi
dr
mark
neal
prichard
depart
pediatr
univers
alabama
birmingham
birmingham
ab
usa
mark
prichard
icar
societi
confer
upon
mark
neal
prichard
isar
award
outstand
contribut
societi
mark
fourth
recipi
major
societi
award
earl
kern
georg
gallaso
erik
de
clercq
present
preced
laudatio
prof
john
drach
mark
join
via
video
link
birmingham
alabama
sadli
mark
pass
away
thursday
june
symposium
dna
virus
memori
publish
antivir
research
john
start
provid
definit
laudatio
honor
prais
individu
highlight
appropri
isar
honor
prais
mark
work
contribut
societi
also
human
qualiti
john
proceed
highlight
mark
contribut
profess
societi
mark
life
mark
complet
bs
microbiolog
univers
minnesota
msc
also
microbiolog
univers
michigan
start
phd
institut
mentorship
charli
shipman
john
met
mark
time
john
charli
work
togeth
even
share
common
lab
space
becam
mentor
mark
complet
phd
mark
postdoctor
train
ed
mocarski
move
pharmaceut
biotech
industri
stint
hybridon
iconix
pharmaceut
medimmun
vaccin
move
back
academia
take
posit
associ
professor
univers
alabama
birmingham
depart
pediatr
quickli
climb
rank
becom
full
professor
director
molecular
diagnost
laboratori
john
reminisc
rich
whitley
help
recruit
mark
back
academia
also
mentor
academ
publish
perish
world
john
briefli
summar
mani
contribut
mark
antivir
research
develop
includ
contribut
invent
new
drug
herpesviru
orthopoxvirus
polyomavirus
papillomavirus
influenza
viru
analys
resist
antivir
drug
specimen
obtain
pediatr
clinic
trial
mark
publish
impress
origin
research
paper
four
book
book
chapter
present
scientif
abstract
major
meet
also
coinventor
issu
patent
develop
softwar
analyz
drugdrug
interact
princip
investig
contract
niaid
help
academia
industri
identifi
new
antivir
mechan
action
overal
secur
impress
research
support
appropri
mark
recogn
societi
william
prusoff
young
investig
awarde
mark
also
activ
member
societi
gener
give
time
poster
award
committe
till
chair
sinc
elect
member
board
director
chair
cochair
program
committe
john
highlight
mark
outstand
scientist
also
excel
colleagu
friend
enjoy
reconnect
colleagu
icar
nih
annual
antivir
contractor
meet
love
dedic
husband
father
also
artist
talent
play
tuba
menomoni
wisconsin
comput
art
put
good
use
drach
shipman
lab
recreat
calvin
hobbl
scienc
arena
resembl
calvin
leroy
townsend
isar
presid
johan
neyt
proceed
present
award
mark
thank
contribut
societi
wish
best
mark
thank
wife
lynn
son
brian
via
video
link
thank
attende
wish
enjoy
lunch
summari
attende
treat
emot
appropri
panegyr
award
ceremoni
longterm
outstand
member
isar
year
icar
isar
introduc
fifth
award
excel
grant
dr
robert
gallo
four
previou
awarde
dr
erik
de
clercq
gertrud
elion
william
prusoff
richard
j
whitley
dr
robert
gallo
award
dissert
focus
mostli
htlv
hiv
also
introduc
global
viral
network
would
later
discuss
presid
christian
md
phd
dr
gallo
start
lectur
discuss
discoveri
htlvi
htlvii
hiv
follow
year
htlv
hiv
two
major
type
human
pathogen
retrovirus
dr
gallo
recount
concept
oncogen
human
virus
gener
retrovirus
particular
face
stiff
resist
time
discoveri
potenti
exist
human
retrovirus
consid
high
interest
consid
like
pathogen
dr
gallo
discuss
discoveri
htlv
start
chang
appreci
human
retrovirus
support
wide
accept
model
aid
could
caus
retroviru
provid
technolog
requir
detect
analyz
human
retrovirus
thu
facilit
discoveri
hiv
discoveri
htlv
hiv
becam
possibl
new
capac
grow
cell
use
interleukin
il
develop
sensit
method
detect
revers
transcriptas
activ
differenti
human
dna
polymeras
produc
adultcel
leukemia
atl
also
associ
myelopathytrop
spastic
paraparesi
hamtsp
inflammatori
disord
immunodefici
htlv
far
conserv
hiv
nonetheless
rel
minor
differ
particularli
end
determin
differ
subtyp
variat
associ
differ
pathogen
b
associ
atl
paralyt
cn
diseas
hamtsp
c
immun
disord
bronchiectasi
basic
nonpathogen
vaccin
antivir
therapi
avail
infect
cure
dr
gallo
discuss
current
evid
indic
antivir
drug
would
use
patholog
induc
virus
patholog
happen
much
late
much
done
prevent
infect
highli
oncogen
approxim
infect
includ
approxim
infect
birth
eventu
develop
atl
global
incid
htlv
around
actual
incid
truli
unknown
yet
larg
region
variat
epidemiolog
still
complet
known
mani
region
includ
sever
highli
popul
one
china
india
exampl
recent
appreci
htlvi
caus
high
morbid
mortal
indigen
australian
popul
incid
high
dr
gallo
express
thought
remain
import
pathogen
research
develop
area
extrem
underfund
consequ
field
still
adequ
develop
succeed
erad
htlvinduc
diseas
contrast
htlv
hiv
replic
much
faster
effici
thu
good
target
antivir
develop
use
azt
first
demonstr
specif
antivir
could
control
system
retroviru
infect
object
data
show
declin
viremia
although
azt
good
control
diseas
evid
collect
use
eventu
culmin
develop
use
combin
therapi
vastli
improv
live
infect
patient
despit
success
howev
hiv
infect
yet
cure
three
main
goal
hiv
preventiontherapeut
first
one
develop
effect
vaccin
unfortun
progress
toward
goal
limit
second
would
complet
cure
elimin
viru
although
much
progress
made
control
diseas
major
progress
yet
toward
cure
infect
howev
third
goal
toward
control
hiv
prevent
antivir
drug
use
preexposur
prophylaxi
latter
approach
alreadi
show
great
potenti
test
potenti
region
erad
viru
dr
gallo
focus
introduc
global
viru
network
gvn
found
member
gvn
independ
global
organ
bring
togeth
expertis
human
virolog
across
world
make
expertis
broadli
avail
crossnat
focus
singl
viru
diseas
rather
bring
togeth
expertis
area
human
virolog
consist
center
excel
affili
organ
countri
contin
current
includ
research
work
virus
differ
field
e
tramontano
et
al
antivir
research
gertrud
elion
memori
awarde
dr
david
evan
introduc
poxvirus
larg
famili
dna
virus
infect
mani
anim
famou
one
variola
viru
caus
agent
smallpox
infect
human
smallpox
highli
contagi
sometim
fatal
diseas
declar
erad
result
massiv
worldwid
vaccin
campaign
first
success
antivir
dna
virus
develop
treat
herpesviru
infect
sever
challeng
treat
smallpox
antivir
uniqu
human
diseas
good
anim
model
atrisk
popul
support
fieldbas
trial
ethic
preclud
human
experiment
perhap
critic
littl
perceiv
need
rais
concern
bioterror
develop
earli
tecovirimat
tpoxx
develop
siga
technolog
first
drug
approv
fda
anim
rule
hoy
target
protein
orthologu
inhibit
viru
exit
tecovirimat
low
resist
barrier
certain
amino
acid
substitut
gene
confer
high
level
resist
yang
et
al
orthopoxvirus
dna
polymeras
pol
highli
conserv
thu
repres
anoth
antivir
target
structur
vaccinia
viru
vacv
dna
pol
report
tarbouriech
et
al
vacv
kb
prototyp
orthopoxviru
replic
high
titer
cytoplasm
structur
call
factori
viru
recombin
link
inextric
replic
recombin
requir
vacv
dna
pol
shown
recombin
frequenc
cell
infect
temperatur
sensit
dna
polymeras
mutant
willer
et
al
vitro
catalysi
recombin
purifi
vacv
dna
pol
gammon
evan
next
david
evan
report
collabor
g
andrei
r
snoeck
rega
institut
leuven
belgium
concern
genet
analysi
cidofovirresist
cdv
r
vacv
nucleosid
phosphon
drug
like
cdv
hpmpc
hpmpa
potent
orthopoxviru
dna
pol
inhibitor
cdv
r
viru
isol
round
passag
resist
map
two
mutat
vacv
dna
pol
andrei
et
al
marker
rescu
transfer
allel
vaccinia
viru
western
reserv
strain
mutat
alon
confer
drug
resist
though
level
resist
confer
singl
mutant
lower
confer
togeth
encouragingli
cdv
r
attenu
pathogen
vacv
wr
strain
intranas
mous
model
cdv
still
protect
lethal
challeng
cdv
r
strain
highlight
collabor
k
hostetl
univers
california
san
diego
la
jolla
synthes
interest
understand
biochem
effect
cdv
diphosph
cdvpp
vacv
dna
pol
mage
et
al
mage
et
al
steadi
state
primer
extens
kinet
vacv
dna
pol
show
cdvpp
caus
polymeras
paus
one
nucleotid
past
site
cdv
incorpor
stepwis
analysi
extens
excis
kinet
show
cdvpp
incorpor
dna
dna
pol
ii
cdvtermin
primer
still
polymeras
substrat
iii
product
extend
poorli
resist
exonucleas
cdvpp
behav
gener
like
chain
termin
effect
vacv
dna
pol
resembl
describ
hcmv
dna
pol
subsequ
david
evan
discuss
hpmpa
bioactiv
vitro
inhibit
vacv
replic
hpmpapp
less
effici
chain
termin
cdvpp
hpmpa
expect
accumul
replic
dna
would
later
becom
templat
strand
vacv
dna
pol
faith
incorpor
nucleotid
opposit
drug
residu
either
cdvpp
hpmpapp
incorpor
templat
rather
primer
strand
howev
templateencod
hpmpa
cdv
strongli
inhibit
primer
extens
david
evan
specul
biochem
data
might
relat
mutat
respons
cdv
r
substitut
map
exonucleas
domain
dna
pol
result
differenti
exonucleas
activ
excis
cdv
end
primer
strand
mutat
map
highli
conserv
dna
pol
may
help
dntp
versu
cdvpp
select
third
class
mutat
base
thumb
dna
pol
presenc
drug
templat
strand
might
inhibit
transit
dna
polymeras
mechan
like
one
strip
thread
block
bolt
passag
nut
e
tramontano
et
al
antivir
research
confer
resist
purin
analogu
hpmpdap
result
highli
attenu
viru
david
evan
suggest
drug
templat
strand
might
inhibit
transit
dna
polymeras
molecul
mutat
may
also
alter
way
dna
enclos
within
thumb
palm
domain
thu
nucleosid
phosphon
may
act
inhibit
viru
polymeras
essenti
damag
dna
fig
support
hypothesi
nmr
structur
dodecam
dna
duplex
contain
cdv
molecul
posit
show
cdv
well
accommod
within
dodecam
dna
duplex
julien
et
al
duplex
destabil
suggest
increas
dynam
around
cdv
thu
templatebear
drug
adduct
creat
barrier
poxvirus
replic
wherea
cell
bypass
templat
damag
special
errorpron
dna
polymeras
poxvirus
replic
cytoplasm
highli
faith
dna
polymeras
david
final
talk
review
whether
nucleosid
phosphon
drug
meet
challeng
pose
diseas
erad
drug
offer
promis
second
smallpox
therapeut
consid
high
barrier
resist
resist
mutant
reduc
fit
mutant
still
drug
sensit
modest
increas
ec
drug
shown
efficaci
sever
anim
model
attribut
may
result
complex
way
drug
inhibit
multipl
step
dna
polymer
reaction
david
suggest
dna
damag
model
deserv
attent
may
base
select
drug
somewhat
surpris
anticanc
activ
later
could
result
dna
repairbypass
system
normal
cell
toler
drug
damag
wherea
repair
defect
cancer
cell
may
sensit
agent
andrei
et
al
memori
award
given
dr
richard
mackman
vice
presid
medicin
chemistri
gilead
scienc
richard
mackman
numer
public
focus
antivir
research
well
name
coinventor
patent
recent
elect
fellow
royal
societi
chemistri
achiev
richard
mackman
lectur
focus
develop
remdesivir
broadspectrum
antivir
remdesivir
initi
known
broadli
activ
antivir
nucleotid
rna
polymeras
inhibitor
shown
potent
activ
ebola
marburg
also
coronavirus
paramyxovirus
flavivirus
lesser
extent
arenavirus
prior
major
ebola
outbreak
occur
west
africa
claim
live
mortal
includ
health
care
worker
focus
librari
nucleosid
analogu
target
viral
rna
polymeras
assembl
nucleosid
analogu
within
gilead
librari
shortli
ebola
outbreak
began
remdesivir
identifi
effect
antiebov
agent
focus
screen
librari
follow
prodrug
optim
discoveri
profil
remdesivir
accomplish
uniqu
publicpriv
partnership
mani
differ
agenc
includ
nih
niaid
usamriid
cdc
vanderbilt
uab
unc
organ
remdesivir
structur
featur
novel
connect
cnucleosid
adenosin
analogu
limit
phosphoryl
parent
nucleosid
requir
util
protid
prodrug
facil
deliveri
monophosph
form
cell
monophosph
rapidli
convert
kinas
activ
form
triphosph
polymeras
inhibitor
detail
richard
mackman
gilead
pursu
addit
structur
modif
structur
activ
relationship
studi
despit
signific
effort
explor
aspect
nucleosid
scaffold
remdesivir
remain
activ
prodrug
due
extrem
urgenc
global
situat
gilead
set
goal
deliv
g
remdesivir
coupl
month
carri
preliminari
vivo
studi
support
ind
success
achiev
synthesi
requir
optim
advanc
program
clinic
highli
impract
cyanat
reaction
requir
full
bodi
suit
protect
process
chemist
requir
gilead
develop
novel
flow
reactor
system
perform
reaction
allow
kilogram
compound
gener
safe
addit
advanc
includ
develop
formul
could
elimin
cold
chain
requir
make
practic
use
african
contin
notabl
remdesivir
use
success
combin
standard
care
two
compassion
case
ebola
infect
famou
scottish
nurs
infect
treat
patient
infant
born
ebola
transmit
mother
current
remdesivir
random
clinic
trial
recent
ebola
outbreak
democrat
republ
congo
three
site
origin
open
enrol
enrol
patient
april
unfortun
one
site
recent
close
due
civil
unrest
underscor
difficulti
develop
drug
set
despit
challeng
remdesivir
remain
one
small
molecul
drug
current
clinic
develop
ebola
potenti
treat
viral
pathogen
given
broad
spectrum
activ
women
scienc
awarde
grace
zhou
select
women
scienc
committe
isar
member
awarde
exemplifi
women
scientist
made
signific
contribut
field
antivir
research
aim
grace
zhou
talk
discuss
career
progress
highlight
subset
current
research
grace
zhou
began
describ
transit
scientist
entrepreneur
note
contrast
academ
research
commerci
industri
consider
manufactur
timelin
howev
found
could
appli
basic
scienc
train
industri
emphas
driven
challeng
time
belief
good
excus
age
gender
educ
continu
learn
found
success
run
busi
lab
reli
heavili
focus
peopl
work
share
advic
audienc
make
sure
select
wise
team
work
recruit
work
work
encourag
motiv
team
instead
push
provid
big
enough
stage
young
peopl
develop
career
overal
approach
manag
center
find
free
spirit
work
hard
emphas
need
allow
employe
mente
make
mistak
take
respons
illustr
philosophi
research
industri
encourag
audienc
play
violin
stage
make
sure
audienc
danc
final
discuss
recogn
grate
unplan
situat
narrat
stori
funder
sought
reach
unexpectedli
invest
million
support
effort
grace
zhou
continu
speak
oncolyt
platform
product
line
drug
formul
emphasi
challeng
manufactur
oncolyt
virus
brief
virus
demonstr
robust
oncolyt
activ
special
backbon
express
upon
singl
inject
tumor
model
nude
mice
viru
suppress
tumor
dosedepend
manner
product
would
appli
treatment
melanoma
grace
zhou
continu
describ
group
recent
investig
particular
function
activ
control
innat
immun
network
respons
hsv
infect
object
identifi
constitut
express
cellular
gene
limit
viral
replic
group
screen
subset
cellular
gene
found
reli
function
constitut
express
induc
cellular
gene
suppress
innat
immun
gene
inim
viral
replic
date
identifi
three
recruit
gene
data
suggest
cellular
gene
recruit
act
independ
least
overlap
set
innat
immun
gene
target
recruit
gene
identifi
far
includ
rigi
cell
deplet
demonstr
impair
abil
suppress
innat
immun
respons
result
reduc
viral
replic
grace
zhou
finish
talk
share
mentor
philosophi
whenev
find
time
great
difficulti
make
cri
time
laugh
conclud
learn
laugh
learn
smile
dengu
fever
caus
infect
dengu
viru
transmit
human
bite
aed
aegypti
aed
albopictu
mosquito
dengu
diseas
major
socialeconom
impact
list
top
global
health
treat
primari
dengu
infect
asymptomat
howev
approxim
lead
febril
ill
dengu
fever
character
rapid
onset
high
fever
combin
plethora
symptom
eg
rash
retroorbit
pain
joint
muscl
pain
back
pain
etc
unfortun
small
fraction
patient
progress
sever
diseas
term
dengu
hemorrhag
diseas
dengu
shock
syndrom
four
serotyp
dengu
viru
cocircul
tropic
subtrop
region
world
infect
one
serotyp
produc
longlast
immun
serotyp
also
gener
nonneutr
antibodi
three
nonneutr
antibodi
enhanc
infect
peopl
infect
differ
serotyp
bind
virion
increas
entri
permiss
cell
fcmediat
uptak
antibodi
viru
complex
result
higher
viral
load
increas
risk
develop
sever
dengu
therapeut
option
treatment
prevent
dengu
fever
limit
current
denguespecif
treatment
avail
develop
small
molecul
antivir
agent
treat
dengu
challeng
due
potenti
small
treatment
window
viremia
close
peak
symptom
start
develop
therefor
remain
open
question
treatment
direct
antivir
result
faster
clearanc
viremia
translat
clinic
benefit
patient
quadrival
dengu
vaccin
recent
licens
use
restrict
peopl
alreadi
dengu
fever
viru
infect
proven
point
care
diagnost
test
prior
vaccin
marnix
van
loock
describ
approach
taken
janssen
develop
potent
panserotyp
firstinclass
dengu
antivir
small
molecul
prevent
treatment
dengu
vulner
popul
includ
travel
live
visit
dengueendem
area
prophylact
approach
like
larger
clinic
impact
oppos
treat
symptomat
individu
replic
may
longer
drive
diseas
target
product
profil
describ
small
molecul
inhibitor
four
dengu
fever
serotyp
prevent
treatment
dengu
drug
would
safe
adult
children
welltoler
without
side
effect
deliv
oral
daili
formul
would
provid
long
term
stabil
stockpil
valu
product
payer
would
reduc
health
care
cost
hospit
frequenc
durat
marnix
van
loock
also
describ
standard
methodolog
use
industri
identifi
drug
candid
includ
high
throughput
screen
lead
identif
lead
optim
importantli
privatepubl
partnership
critic
address
neglect
tropic
diseas
illustr
collabor
academia
partnership
ku
leuven
wellcom
trust
key
program
discuss
partnership
winwin
scenario
develop
combin
strength
industri
eg
pharmacokinet
adm
preclin
data
packag
necessari
regulatori
file
clinic
develop
etc
academia
basic
research
identifi
new
target
mechan
action
studi
resist
evalu
vivo
model
etc
overal
ultim
goal
activ
help
build
healthi
commun
worldwid
innov
impact
healthcar
solut
partnership
specif
program
stop
elimin
dengu
keynot
speaker
confer
dian
griffin
present
lectur
topic
focus
pathogenesi
immun
measl
viru
mev
nowaday
produc
sever
major
outbreak
result
insuffici
vaccin
coverag
dr
griffin
start
analyz
strict
human
virus
infect
anoth
host
persist
human
popul
mani
hiv
herp
virus
hepat
c
viru
persist
popul
long
persist
latent
infect
howev
rna
virus
mev
produc
acut
infect
fulli
resolv
transmiss
short
period
infect
host
develop
longlast
immun
yet
mev
remain
one
top
caus
mortal
among
infecti
diseas
world
long
immun
mev
discov
even
diseas
known
result
viral
infect
virus
even
known
exist
outbreak
faro
island
peter
ludvig
panum
danish
physician
observ
measl
contagi
found
incub
time
day
attack
rate
aliv
time
previou
outbreak
island
year
lifelong
immun
diseas
thu
becam
clear
know
antibodi
level
remain
high
year
old
peopl
infect
children
extrem
high
attack
rate
mev
consequ
high
r
descriptor
number
peopl
get
infect
case
mev
comparison
mump
polio
smallpox
flu
mev
transmit
respiratori
rout
first
infect
respiratori
tract
lymphoid
cell
distribut
viru
bodi
onset
clinic
symptom
presymptomat
acut
infect
difficult
studi
human
macaqu
model
lymphocyt
predominantli
infect
cell
although
higher
percentag
b
lymphocyt
infect
cell
popul
contribut
equal
viral
spread
b
lymphocyt
infect
mostli
memori
cell
express
lymphocyt
mev
receptor
receptor
vaccin
strain
peripher
blood
mononuclear
cell
pbmc
distribut
viru
skin
typic
rash
occur
infect
cell
present
rash
lesion
immunosuppress
patient
basic
rashbut
also
fail
clear
infect
mev
also
infect
epitheli
cell
use
receptor
measl
immunosuppress
point
death
result
complic
infect
mainli
diarrhea
otiti
media
pneumonia
case
per
mev
infect
respect
encephalomyel
subacut
scleros
panenceph
sspe
far
less
common
seriou
complic
sspe
fatal
neurolog
slow
diseas
occur
year
acut
infect
innat
immun
respons
effect
control
infect
mev
paramyxovirus
inhibit
ifn
induct
mostli
action
nonstructur
protein
v
c
type
ifn
produc
inhibit
innat
immun
respons
total
howev
cytokin
still
produc
mev
cultur
site
rash
clear
viral
rna
detect
children
least
month
afterward
hiv
hivindividu
longer
term
persist
evalu
persist
viral
rna
reproduc
macaqu
viral
rna
linearli
declin
month
infect
measur
immun
suppress
time
detect
viral
rna
enhanc
suscept
infect
persist
much
longer
year
genom
variabl
persist
genom
analyz
persist
rna
includ
messeng
rna
ongo
immun
respons
suggest
mev
protein
express
regardless
persist
viral
messeng
rna
evid
longterm
infect
ever
result
transmiss
antibodi
respons
critic
protect
particular
avid
antibodi
neutral
antibodi
protect
diseas
lower
titr
protect
infect
neutral
antibodi
bind
region
mev
h
protein
receptor
minim
antigen
drift
moreov
mev
truli
monotyp
viru
vaccin
use
today
develop
isol
john
elder
blood
child
name
edmonston
current
vaccin
deriv
origin
isol
slightli
differ
passag
histori
use
two
dose
first
either
subcutan
intramuscular
inject
month
level
plasma
mev
antibodi
rais
fast
rash
matur
antibodi
respons
rather
slow
qualiti
antibodi
critic
protect
moreov
number
mev
antibodi
secret
cell
blood
increas
rash
clear
likewis
number
secret
cell
increas
quickli
infect
blood
peak
later
germin
center
howev
number
mev
respons
cell
continu
increas
late
infect
vaccin
replic
better
wt
viru
cell
type
pbmc
wt
produc
infecti
unit
ml
wherea
vaccin
produc
none
surprisingli
wt
mev
infect
induc
much
better
antibodi
respons
decreas
much
time
wherea
result
vaccin
mev
antibodi
respons
mmr
vaccin
still
around
origin
titr
year
vaccin
consequ
secondari
vaccin
failur
infrequ
estim
around
year
vaccin
effect
point
thank
basic
domest
case
usa
till
elimin
declar
till
import
case
per
year
produc
small
domest
outbreak
howev
decreas
vaccin
result
reemerg
first
peak
case
second
one
ongo
right
almost
case
first
four
month
year
problem
limit
us
number
case
quadrupl
worldwid
vast
major
current
case
mev
occur
unvaccin
peopl
particular
vaccin
yet
young
age
less
case
occur
patient
receiv
two
dose
result
high
r
howev
high
vaccin
coverag
around
higher
requir
interrupt
transmiss
prevent
outbreak
challeng
vaccin
differ
develop
countri
biggest
challeng
achiev
essenti
high
coverag
lie
health
infrastructur
cold
chain
avail
needl
syring
need
suffici
number
skill
train
health
worker
compound
requir
two
dose
develop
countri
grow
challeng
regard
vaccin
accept
compound
safeti
worri
consider
balanc
individu
right
public
health
evid
secondari
vaccin
failur
major
contribut
factor
ongo
recurr
outbreak
restor
vaccin
coverag
paramount
stop
current
ongo
measl
outbreak
jefferi
taubenberg
describ
influenza
pandem
worst
natur
disast
histori
although
clinic
sampl
collect
time
pandem
autopsi
specimen
use
sequenc
reconstruct
viru
genom
describ
influenza
viru
novel
founder
viru
initi
current
pandem
era
influenza
pandem
season
epidem
sinc
caus
descend
viru
import
lesson
learn
pandem
may
need
produc
better
antivir
broadli
protect
univers
influenza
vaccin
necessit
better
understand
correl
immun
pathogen
human
anim
model
infect
frederick
hayden
describ
recent
advanc
use
antivir
treat
influenza
discuss
use
convalesc
serum
intraven
immunoglobulin
addit
evalu
intraven
rout
administr
zanamivir
identifi
potenti
threshold
possibl
neuraminidas
inhibitor
also
describ
three
oral
avail
influenza
viru
inhibitor
favipiravir
pimodivir
baloxavir
marboxil
target
compon
influenza
polymeras
complex
pa
endonucleas
respect
antivir
drug
combin
drug
studi
neuraminidas
inhibitor
show
synergi
preclin
model
combin
current
studi
hospit
influenza
patient
addit
emphas
antivir
combin
offer
best
strategi
enhanc
potenc
reduc
select
resist
treat
higherrisk
influenza
patient
hospit
seriou
ill
florian
krammer
describ
influenza
hemagglutinin
ha
stalk
base
univers
influenza
vaccin
membraneproxim
stalk
domain
viral
ha
exhibit
high
degre
conserv
across
influenza
viru
subtyp
monoclon
antibodi
direct
region
typic
show
broad
neutral
activ
use
chimer
ha
combin
stalk
globular
head
avian
influenza
virus
provid
crossprotect
phylogenet
subtyp
sequenti
vaccin
mice
ferret
chimer
ha
construct
share
stalk
domain
diverg
head
domain
success
boost
broadli
neutral
antibodi
titer
conserv
epitop
ha
stalk
also
interf
viru
transmiss
anim
data
suggest
vaccin
strategi
potenti
provid
broad
influenza
viru
protect
human
open
lectur
emerg
virus
symposium
maria
van
kerkhov
review
world
health
organ
program
middl
east
respiratori
syndrom
mer
etiolog
agent
mer
coronaviru
merscov
import
zoonot
pathogen
sinc
caus
repeat
outbreak
mostli
animaltohuman
spread
limit
humantohuman
transmiss
dromedari
camel
natur
host
human
case
report
direct
indirect
link
camel
overal
basic
reproduct
rate
r
measur
transmiss
potenti
infecti
diseas
less
one
howev
maria
van
kerkhov
note
higher
attack
rate
health
care
set
r
reach
high
six
also
highlight
high
case
fatal
rate
cfr
approxim
sinc
indic
number
like
overestim
sinc
mild
case
like
miss
current
surveil
system
mer
global
risk
high
public
health
secur
econom
impact
countri
report
case
date
although
case
report
saudi
arabia
south
korean
outbreak
estim
econom
cost
eight
billion
dollar
maria
van
kerkhov
point
global
risk
associ
travel
area
merscov
circul
dromedari
camel
subsequ
humantohuman
transmiss
risk
reduc
better
surveil
camel
human
popul
area
viru
known
circul
aggress
contact
trace
identifi
peopl
subclin
infect
fit
enough
travel
serv
potenti
sourc
exposur
sinc
e
tramontano
et
al
antivir
research
major
peak
case
number
result
nosocomi
outbreak
cfr
reach
specif
health
care
set
mer
global
work
plan
base
improv
prepared
prevent
respons
high
threat
respiratori
pathogen
like
mer
mer
list
blueprint
prioriti
pathogen
due
epidem
potenti
current
lack
avail
countermeasur
urgent
need
research
better
understand
transmiss
merscov
dromedari
animalhuman
interfac
maria
van
kerkhov
finish
discuss
potenti
therapeut
mer
one
clinic
trial
ongo
miracl
clinic
trial
saudi
arabia
explor
combin
lopinavirritonavir
first
control
trial
potenti
therapi
mer
time
meet
individu
enrol
miracl
trial
addit
effort
develop
vaccin
camel
human
fund
sever
institut
includ
coalit
epidem
prepared
innov
cepi
maria
van
kerkhov
also
mention
mer
app
develop
current
avail
appl
googl
play
applic
provid
updat
mersspecif
guidanc
materi
investig
tool
base
latest
scientif
knowledg
experi
member
state
deal
mer
conclud
remark
valuabl
impact
reduc
number
human
case
death
sinc
second
lectur
emerg
virus
symposium
emili
gurley
provid
perspect
insight
nipah
viru
niv
consid
one
danger
agent
nipah
cfr
rang
malaysia
bangladesh
niv
zoonot
pathogen
maintain
pteropu
bat
wide
geograph
distribut
reach
eastern
australia
relat
hendra
viru
caus
equin
human
case
sever
respiratori
neurolog
diseas
fortun
merscov
rel
ineffici
niv
persontoperson
transmiss
howev
infect
progress
acut
enceph
respiratori
complic
surviv
experi
neurolog
sequela
contact
survey
conduct
show
asymptomat
infect
like
rare
bangladesh
nikolay
et
al
emili
gurley
also
discuss
surveil
effort
transmiss
data
poor
infect
control
measur
often
overcrowd
hospit
set
bangladesh
model
combin
healthcar
util
survey
activ
niv
case
find
effort
three
bangladesh
hospit
suggest
half
actual
case
detect
hegd
et
al
term
transmiss
male
experienc
breath
difficulti
found
effici
persontoperson
transmiss
nikolay
et
al
review
emili
gurley
caregiv
greatest
risk
infect
understaf
medic
center
base
bangladeshi
cultur
caregiv
larg
famili
member
spous
especi
risk
exposur
bodi
fluid
contain
infecti
viru
facilit
transmiss
emerg
viral
diseas
avail
treatment
although
promis
new
preclin
data
recent
publish
suggest
remdesivir
may
use
treat
niv
infect
diseas
caskey
et
al
emili
gurley
highlight
individu
expos
infecti
viru
contamin
date
palm
sap
shorter
incub
period
rapid
diseas
progress
compar
patient
infect
persontoperson
transmiss
diagnosi
gener
occur
day
death
best
possibl
circumst
case
fatal
ratio
cfr
approxim
exposur
rout
therapeut
intervent
may
feasibl
case
acquir
persontoperson
transmiss
longer
incub
time
slower
evolut
sever
diseas
earlier
diagnosi
day
improv
prospect
surviv
approxim
cfr
persontoperson
transmiss
opportun
antivir
treatment
addit
effect
antivir
rapid
diagnost
highest
prioriti
emili
gurley
wish
list
much
need
abl
initi
treatment
good
treatment
one
day
avail
infect
control
intervent
earlier
conclud
ultim
mitig
pandem
risk
associ
niv
requir
combin
approach
includ
prophylact
measur
person
protect
equip
care
patient
implement
sound
infect
control
measur
improv
surveil
educ
vaccin
atrisk
individu
healthcar
worker
consum
date
palm
sap
costeffect
shelfstabl
easi
administ
antivir
third
lectur
emerg
virus
session
scott
weaver
recogn
leader
field
arbovirolog
tackl
subject
predict
arbovir
epidem
began
review
outbreak
arbovir
diseas
result
enzoot
epizoot
spillov
event
lead
human
infect
although
zika
dengu
virus
human
amplif
transmiss
cycl
involv
highlight
import
vector
vectori
capac
aed
aegypti
superior
regard
evolut
aegypti
close
associ
human
led
major
role
transmiss
urban
arbovirus
includ
yellow
fever
chikungunya
virus
discuss
proactiv
approach
employ
deep
sequenc
nonhuman
primat
nhp
arthropod
vector
sampl
identifi
new
emerg
reemerg
arbovirus
potenti
caus
human
diseas
emphas
need
develop
cell
cultur
rodent
nhp
model
learn
human
impact
potenti
parallel
vector
compet
studi
critic
aed
speci
aegypti
albopticu
need
inform
potenti
risk
scott
weaver
went
number
import
arbovirus
discuss
public
health
concern
pose
mayaro
viru
mayv
well
recogn
despit
human
case
regularli
detect
dengueendem
region
south
central
america
mayv
great
urban
emerg
potenti
viremia
may
high
enough
transmiss
urban
mosquito
mayv
enzoot
region
overlap
consider
venezuelan
equin
enceph
viru
veev
outbreak
potenti
base
mutat
lead
major
epizoot
spillov
human
occur
columbia
venezuela
well
high
level
human
viremia
also
note
potenti
risk
import
rift
valley
fever
viru
like
veev
japanes
enceph
viru
amplifi
domest
anim
avail
compet
mosquito
rvfv
unit
state
well
document
evid
vectori
capac
lack
also
refer
recent
experiment
infect
model
studi
althous
et
al
vanchier
et
al
support
concern
zika
viru
zikv
sylvat
cycl
establish
area
suscept
nhp
host
present
zikv
spillback
enzoot
cycl
would
make
elimin
near
imposs
final
scott
weaver
discuss
stochast
natur
arbovir
emerg
suggest
founder
effect
reduc
fit
epistasi
constrain
evolut
process
new
world
chikungunya
viru
lineag
excel
exampl
predict
epistat
interact
like
prevent
adapt
albopictu
occur
african
lineag
tsetsarkin
et
al
founder
effect
also
appear
play
zikv
scott
weaver
also
indic
uncertainti
regard
global
warm
affect
arbovir
diseas
addit
alter
current
rang
vector
speci
increas
temperatur
sometim
harm
viru
mosquito
moreov
hotter
weather
may
limit
outdoor
activ
therebi
reduc
human
exposur
risk
marina
caskey
review
preclin
clinic
evid
support
potenc
efficaci
use
passiv
immunotherapi
broadli
neutral
antibodi
bnab
treat
hiv
individu
bnab
uniqu
often
target
conserv
viral
epitop
otherwis
highli
variabl
antigen
region
envelop
combin
antiretrovir
therapi
art
highli
success
suppress
viral
replic
prevent
diseas
viru
transmiss
howev
erad
latent
infect
viral
reservoir
immunotherapi
bnab
offer
advantag
antibodi
safe
rel
long
halflif
allow
longer
dose
scheme
number
bnab
identifi
date
owe
vulner
envelop
glycoprotein
mouquet
secondgener
bnab
target
variou
epitop
envelop
trimer
includ
antibodi
bind
site
eg
loop
eg
membran
proxim
region
mper
eg
antibodi
current
investig
clinic
studi
caskey
et
al
exampl
show
except
breadth
potenc
vitro
protect
suppress
infect
anim
model
singl
agent
bnab
safe
effect
reduc
viremia
combin
test
macaqu
model
led
prolong
control
infect
evid
escap
either
antibodi
caskey
et
al
human
combin
two
antibodi
confer
protect
doubl
combin
baron
et
al
mendoza
et
al
greater
protect
may
achiev
tripl
combin
importantli
bnab
may
boost
effect
tcell
mediat
cytotox
immun
respons
lead
elimin
infect
cell
reduct
clearanc
viral
reservoir
effect
achiev
antiretrovir
therapi
current
effort
focu
identifi
steril
complet
elimin
viru
function
cure
suppress
viral
load
limit
detect
without
need
antiretrovir
therapi
infect
bnab
may
use
combin
viru
latenc
revers
agent
vaccin
effect
induc
cytotox
lymphocyt
ctl
mediat
kill
infect
cell
conclus
addit
prevent
new
infect
bnab
may
clear
viru
directli
kill
infect
cell
produc
immun
complex
enhanc
host
immun
viru
aim
achiev
longterm
viral
remiss
howard
gendelman
focus
potenti
use
longact
antiretrovir
step
toward
improv
treatment
outcom
highlight
recent
advanc
dash
et
al
despit
great
success
current
antiretrovir
regimen
reduc
viru
transmiss
transform
hiv
infect
manag
chronic
infect
toxic
adher
remain
caus
concern
longact
formul
antiretrovir
may
improv
regimen
adher
reduc
viral
drug
resist
howard
gendelman
introduc
concept
longact
slow
effect
releas
antiretrovir
therapi
laserart
dash
et
al
hydrophob
lipophil
nanocryst
serv
agent
capabl
slowli
releas
antiretrovir
prodrug
antiretrovir
modifi
improv
drug
potenc
enhanc
cell
membran
permeabl
facilit
encapsul
nanocryst
may
rapidli
taken
cell
distribut
target
tissu
gendelman
et
al
one
exampl
present
nanoformul
cabotegravir
hiv
integras
inhibitor
packag
stabl
particl
high
drug
load
capac
capabl
target
monocytemacrophag
zhou
et
al
suscept
hiv
infect
second
exampl
also
integras
inhibitor
dolutegravir
hydrophob
lipophil
modifi
prodrug
encapsul
poloxam
nanoformul
sillman
et
al
confer
long
biolog
halflif
cell
tissu
drug
penetr
antiretrovir
potenc
current
futur
effort
new
drug
formul
may
lead
chang
paradigm
antiretrovir
treatment
improv
drug
efficaci
patient
outcom
theranost
nanoparticl
multifunct
nanosystem
combin
singl
nanoparticl
may
provid
unpreced
advantag
current
treatment
strategi
longact
drug
formul
requir
lessfrequ
dose
offer
opportun
improv
adher
provid
patient
valuabl
altern
treatment
forgiv
conveni
antiretrovir
drug
may
formul
extend
durat
dose
exdd
option
lead
prolong
month
dose
interv
barrett
et
al
efda
novel
nucleosid
analogu
display
differenti
mechan
action
nucleosid
revers
transcriptas
transloc
inhibitor
nrtti
compar
approv
nucleosid
revers
transcriptas
inhibitor
nrti
alexandr
et
al
revers
transcriptas
use
efdatp
substrat
effici
natur
substrat
datp
acostahoyo
scott
inhibit
revers
transcriptas
first
incorpor
terminu
incorpor
prevent
addit
nucleotid
block
transloc
primer
strand
viral
polymeras
michailidi
et
al
exhibit
prolong
intracellular
persist
excel
potenc
evalu
preclin
hiv
treatment
preexposur
prophylaxi
prep
demonstr
robust
protect
rhesu
macaqu
rm
simianhuman
immunodefici
viru
shiv
model
markowitz
et
al
shown
gener
welltoler
administ
onetim
dose
mg
adult
subject
halflif
peripher
blood
mononuclear
cell
pbmc
subject
h
render
compat
varieti
potenti
dose
regimen
singledos
treatment
dose
low
mg
lead
robust
vl
declin
subject
barrett
et
al
matthew
et
al
result
exquisit
potenc
longact
pk
profil
robust
efficaci
candid
exdd
formul
drug
may
dispers
within
polym
exhibit
control
degrad
bioerod
nonerod
gener
monolith
matrix
implant
dimens
suitabl
subcutan
administr
implant
design
achiev
broad
rang
drug
releas
characterist
durat
achiev
optim
drug
load
polym
composit
implant
barrett
et
al
present
highlight
backup
medicin
chemistri
effort
novel
nucleosid
chemistri
develop
well
optim
implant
formul
e
tramontano
et
al
antivir
research
symposium
three
present
given
outstand
scientist
field
goal
minisymposium
bring
medicin
chemistri
closer
broad
audienc
describ
method
approach
chemist
use
develop
new
potenti
antivir
agent
first
lectur
given
katherin
seleyradtk
chemistri
second
lectur
present
andrea
brancal
molecular
model
third
lectur
given
anthoni
keef
compound
librari
develop
articl
review
develop
nucleosid
analogu
antivir
drug
written
target
audienc
virologist
nonchemist
well
chemist
may
familiar
histori
field
result
import
role
field
medicin
chemistri
sever
decad
nucleosid
remain
key
focu
antivir
research
effort
natur
occur
nucleosid
repres
uniqu
start
point
drug
design
due
involv
numer
critic
biolog
process
well
serv
essenti
build
block
dna
rna
synthesi
nucleosidetid
analogu
mimic
structur
natur
nucleosid
recogn
cellular
viral
enzym
modif
structur
typic
lead
disrupt
termin
replic
biolog
process
rather
provid
simpl
chronolog
account
walk
us
thought
process
advanc
synthet
chemistri
lesson
learn
antivir
test
led
sever
molecul
move
forward
clinic
eventu
approv
human
therapi
other
discard
nucleosidetid
analogu
market
approv
use
treat
virus
cancer
condit
mani
clinic
preclin
trial
lectur
katherin
seleyradtk
focus
first
earli
rel
simplist
chang
made
nucleosid
scaffold
begin
modif
nucleosid
sugar
arac
arabinosederiv
nucleosid
analogu
extend
review
recent
develop
focus
particularli
complex
modif
particularli
involv
multipl
chang
nucleosid
scaffold
eg
sofosbuvir
remdesivir
new
broadspectrum
antivir
develop
gilead
scienc
explain
certain
drug
success
develop
major
candid
compound
encount
barrier
lowyield
synthet
rout
toxic
problem
led
abandon
concurr
also
discuss
hurdl
type
compound
must
overcom
eg
activ
lack
phosphoryl
overcom
use
monophosph
triphosph
prodrug
form
parent
nucleosid
analogu
lectur
serv
provid
inform
use
overview
import
nucleosid
analogu
antivir
research
well
issu
solut
surround
develop
andrea
brancal
focus
present
use
computeraid
techniqu
particular
structurebas
drug
design
method
earli
stage
antivir
drug
discoveri
support
discuss
provid
exampl
publish
work
start
summari
work
identif
novel
chikv
proteas
inhibitor
describ
structur
avail
viral
protein
start
project
henc
homolog
model
built
use
virtual
screen
protocol
librari
commerci
avail
compound
best
rank
compound
result
silico
result
purchas
test
antivir
assay
biolog
evalu
result
identif
promis
compound
low
micromolar
antivir
activ
interestingli
hit
optim
follow
carri
use
tradit
systemat
structur
activ
explor
without
support
computeraid
method
andrea
point
highlight
time
direct
assay
activ
avail
henc
direct
evid
compound
activ
proteas
miss
howev
shortli
public
result
anoth
group
test
select
molecul
report
andrea
group
report
inhibitori
effect
chikv
chemic
scaffold
move
second
exampl
taken
current
work
model
approach
similar
previou
one
case
emphasi
differ
ligandbas
filter
use
virtual
screen
biolog
target
case
noroviru
polymeras
structur
enzym
resolv
also
complex
inhibitor
group
use
inform
filter
compound
librari
use
shapebas
approach
select
compound
similar
volum
crystal
ligand
compound
result
procedur
dock
polymeras
promis
one
test
biochem
assay
purifi
enzym
two
interest
hit
identifi
low
micromolar
inhibitori
activ
howev
compound
show
good
antivir
activ
cellbas
assay
final
andrea
talk
develop
interact
hapticdriven
molecular
dock
simul
particular
focus
discuss
tri
develop
system
take
account
inducedfit
effect
small
molecul
target
upon
bind
although
remain
complex
problem
solv
andrea
show
current
tool
abl
gener
accur
result
least
rel
simpl
system
anthoni
keef
xchem
compani
last
eight
year
licens
sixti
program
rang
partner
larg
pharmaceut
compani
small
biotech
report
new
strategi
drug
discoveri
use
dnaencod
chemic
librari
tradit
drug
discoveri
project
initi
use
ht
limit
number
compound
one
screen
onecompoundonewel
paradigm
typic
singledigit
million
dnaencod
chemic
librari
allow
screen
combinatoriallygener
librari
compound
exceed
numer
size
ht
collect
five
order
magnitud
compound
dnaencod
chemic
librari
coval
attach
uniqu
dna
barcod
sequenc
use
understand
chemic
histori
encod
smallmolecul
attach
therebi
elucid
ident
dnaencod
chemic
librari
gener
solut
splitandpool
chemic
synthesi
individu
isol
compart
use
contain
build
block
instal
reaction
along
correspond
ligat
short
dna
tag
sequenc
encod
build
block
ident
fig
librari
util
affinitymedi
screen
rare
individu
librari
member
bind
protein
target
separ
nonbind
protein
captur
stringent
wash
remov
nonbind
proteinbind
smallmolecul
identifi
pcr
amplif
sequenc
resynthesi
biochem
biophys
assay
use
determin
identifi
smallmolecul
bind
target
manner
appropri
moder
target
activ
e
tramontano
et
al
antivir
research
approach
offer
potenti
discoveri
entir
new
chemic
matter
inhibit
otherwis
modul
target
interest
either
compound
dnaencod
chemic
librari
collect
coval
irrevers
inhibitor
compound
dnaencod
electrophilecap
coval
librari
wwwxchemrxcom
akeef
xchemrxcom
year
meet
includ
two
session
focus
particular
viru
diseas
disciplin
approach
rather
provid
gener
view
new
direct
challeng
gener
field
antivir
research
michael
jacob
describ
three
case
studi
patient
sever
yellow
fever
viru
yfv
diseas
first
clinic
use
experiment
antivir
nucleosid
analogu
galidesivir
biocryst
pharmaceut
first
case
studi
german
travel
return
brazil
present
fever
shiver
prostrat
conjunctiv
suffus
jaundic
hepatomegali
patient
receiv
yellow
fever
vaccin
patient
posit
yellow
fever
viru
pcr
detect
rapidli
progress
acut
liver
failur
acut
renal
failur
coma
dr
jacob
describ
epidemiolog
natur
histori
yellow
fever
viru
infect
yellow
fever
classic
describ
two
phase
character
initi
viremia
associ
acut
febril
ill
last
day
follow
remiss
h
follow
brief
remiss
period
intox
last
day
symptom
includ
gastroinest
disturb
liver
involv
jaundic
increasingli
sever
clinic
present
lead
death
patient
although
histor
descript
report
infecti
viru
isol
stage
pcr
detect
viral
rna
abund
approxim
infect
progress
intox
phase
diseas
pro
con
liver
transplant
use
antivir
intervent
discuss
second
case
studi
describ
man
histori
thymectomi
thymoma
year
prior
experienc
abrupt
onset
fever
day
yellow
fever
viru
vaccin
present
day
postil
onset
fever
tachycardia
hypotens
jaundic
yellow
fever
viru
posit
pcr
detect
subsequ
develop
hemophagocyt
lymphohistiocytosi
progress
multiorgan
failur
yellow
fever
viru
vaccin
associ
vaccineinduc
viscerotrop
diseas
case
describ
literatur
result
fatal
outcom
total
patient
histori
thymoma
rare
diseas
patient
receiv
optim
support
intens
care
treatment
direct
treat
hemophagocyt
lymphohistiocytosi
patient
also
receiv
experiment
antivir
compound
galidesivir
nucleosid
analogu
broad
spectrum
antivir
activ
shown
efficaci
hamster
model
yellow
fever
viru
infect
treatment
galidesivir
associ
mild
progress
decreas
yellow
fever
viru
rna
patient
plasma
unfortun
patient
succumb
multiorgan
failur
third
case
studi
man
also
underw
thymectomi
thymoma
receiv
yellow
fever
vaccin
error
plan
trip
central
america
patient
clinic
well
h
postvaccin
treatment
team
decid
administ
galidesivir
postexposur
prophylact
therapi
reduc
risk
vaccin
relat
complic
spike
viremia
yellow
fever
viru
rna
urin
measur
rtqpcr
vaccin
galdiesivir
treatment
patient
resolv
infect
without
signific
clinic
consequ
develop
antibodi
yellow
fever
viru
victoria
olson
present
challeng
vaccin
endem
orthopoxviru
diseas
monkeypox
potenti
approach
overcom
monkeypox
orthopoxviru
caus
zoonot
infect
human
lead
diseas
clinic
resembl
smallpox
viru
endem
western
central
africa
caus
small
outbreak
local
individu
two
distinct
clade
viru
isol
central
africa
associ
mortal
rate
attack
rate
per
gener
popul
per
healthcar
worker
patient
treat
support
care
treatment
symptom
sinc
licens
vaccin
therapeut
agent
monkeypox
vaccin
origin
develop
prevent
smallpox
use
erad
intensifi
smallpox
vaccin
campaign
led
also
shown
activ
monkeypox
infect
vaccin
compos
live
vaccinia
viru
close
relat
orthopoxviru
replic
local
site
inocul
gener
robust
cellular
humor
immun
respons
vaccin
contraind
peopl
eczema
immunecompromis
condit
due
high
risk
sever
side
effect
lifethreaten
although
effect
vaccin
recommend
prevent
monkeypox
due
concern
safeti
imvamun
thirdgener
smallpox
vaccin
deriv
attenu
modifi
vaccinia
ankara
mva
strain
vaccin
test
human
subject
includ
hiv
individu
individu
atop
dermat
stockpil
strateg
nation
stockpil
sever
advers
event
observ
clinic
trial
sinc
smallpox
erad
howev
efficaci
vaccin
evalu
anim
orthopoxviru
infect
goal
cdc
poxviru
rabi
branch
protect
public
emerg
viral
threat
monkeypox
end
cdc
initi
surveil
program
tshuapa
provinc
democrat
republ
congo
drc
collabor
kinshasa
school
public
health
inrb
drc
ministri
health
surveil
program
identifi
approxim
confirm
case
per
year
tshuapa
provinc
program
provid
platform
understand
effect
countermeasur
treatment
orthopoxviru
infect
realworld
set
studi
third
gener
smallpox
vaccin
imvamun
enrol
cohort
adult
healthcar
worker
risk
monkeypox
drc
object
studi
evalu
safeti
immunogen
effect
imvamun
prevent
human
monkeypox
ethic
regulatori
logist
challeng
deliv
vaccin
product
requir
cold
chain
remot
area
drc
overcom
discuss
differ
color
indic
relationship
build
block
ident
encod
sequenc
tag
e
tramontano
et
al
antivir
research
chikungunya
viru
caus
spectrum
ill
rang
asymptomat
infect
sever
febril
ill
mark
incapacit
arthralgia
sever
strategi
discuss
identifi
drug
candid
treat
chikungunya
infect
use
approv
investig
drug
drug
repurpos
reduc
time
cost
candid
develop
abbrevi
clinic
studi
broadspectrum
antivir
test
chikungunya
replic
includ
ribavirin
favipiravir
sofosbuvir
shown
level
efficaci
vitro
host
target
agent
anoth
pathway
therapeut
develop
reduc
select
resist
may
result
broad
spectrum
activ
howev
host
pathway
also
result
use
limit
toxic
phenotyp
screen
use
identifi
chemic
matter
inhibit
viru
replic
high
throughput
screen
methodolog
identifi
novel
compound
hit
optim
target
identif
straightforward
final
targetbas
assay
develop
identifi
specif
inhibitor
viral
enzym
necessari
viru
replic
select
exampl
present
illustr
strategi
compound
triazolopyrimidin
identifi
phenotyp
screen
compound
activ
chikungunya
cellbas
replic
assay
ec
valu
cc
valu
structur
activ
relationship
guid
medicin
chemistri
effort
improv
potenc
result
identifi
sever
area
molecul
chemic
modifi
potenti
improv
activ
approach
led
identif
sever
novel
madtp
compound
ec
valu
cellbas
replic
assay
approxim
resist
map
identifi
mutat
gene
correl
reduc
suscept
madtp
compound
compound
shown
inhibit
guanylyl
activ
protein
viru
variant
contain
mutat
resist
inhibitori
effect
madtp
compound
result
optim
campaign
identifi
compound
ec
valu
rang
cc
valu
gori
phdvirovet
leuven
belgium
lectur
nesya
gori
virovet
leuven
belgium
review
concept
use
smallmolecul
drug
halt
spread
viral
diseas
livestock
began
note
billion
anim
consum
food
year
demand
anim
protein
expect
increas
despit
avail
numer
vaccin
howev
livestock
product
still
lost
diseas
death
given
success
human
smallmolecul
antivir
gain
attent
altern
prevent
treatment
livestock
diseas
talk
highlight
potenti
antivir
therapi
contain
outbreak
exot
infect
use
classic
swine
fever
compound
bpip
exampl
experiment
studi
piglet
bpip
reduc
virem
period
viral
load
highli
effect
prevent
transmiss
infect
untreat
sentinel
vrancken
et
al
vrancken
et
al
model
studi
shown
econom
viabl
control
polici
backer
et
al
smallmolecul
antivir
may
also
role
play
endem
diseas
control
costeffect
reduc
product
loss
improv
anim
health
welfar
collett
phd
virodefens
inc
rockvil
md
usa
marc
collett
virodefens
chevi
chase
md
usa
review
expect
need
antivir
therapi
polio
endgam
three
decad
infant
immun
campaign
brought
world
close
goal
erad
case
paralyt
diseas
recogn
three
countri
howev
use
live
attenu
oral
vaccin
opv
result
unanticip
consequ
underimmun
popul
vaccin
viru
spread
occasion
revert
virul
moreov
person
immunodefici
disord
viru
may
establish
persist
infect
shed
year
plan
cessat
opv
use
address
former
erad
requir
treatment
chronic
infect
person
current
accept
two
antivir
differ
mechan
action
need
marc
describ
current
statu
two
lead
compound
pocapavir
act
stabil
viral
capsid
prevent
disassembl
inhibitor
enteroviru
proteas
highli
activ
three
strain
vaccin
viru
show
synergist
activ
minim
toxic
date
pocapavir
test
efficaci
human
volunt
collett
et
al
result
suggest
combin
therapi
requir
block
evolut
resist
viru
third
present
subhash
vasudevan
duken
univers
singapor
review
develop
antivir
dengu
zika
virus
note
particular
effort
novarti
institut
tropic
diseas
highlight
current
articl
antivir
research
summar
year
dengu
studi
lim
note
compound
current
develop
janssen
pharmaceut
target
four
dengu
viru
serotyp
candid
molecul
activ
serotyp
recent
paper
bartenschlag
group
valid
dengu
protein
swiss
armi
knife
could
ideal
antivir
target
especi
given
interact
precursor
version
plaszczyca
et
al
opportun
target
dengu
zika
viru
nucleosideanalogu
inhibitor
remdesivir
gilead
also
suggest
base
extens
structur
function
similar
protein
replic
mechan
rna
virus
also
briefli
review
work
small
biotech
compani
attempt
develop
therapeut
antibodi
dengu
zika
yellow
fever
viru
orf
herpesvirus
hcmv
establish
lifelong
infect
character
differ
stage
lytic
replic
viral
gene
express
product
infecti
viru
latenc
limit
gene
express
presenc
viral
dna
infecti
viru
reactiv
signal
stimul
exit
latenc
lytic
cycl
hcmv
complex
lifestyl
escap
immun
surveil
persist
host
infect
numer
tissu
variou
cell
type
herpesviru
infect
world
popul
immunocompet
individu
infect
gener
asymptomat
though
viru
associ
chronic
diseas
eg
cardiovascular
cancer
viru
also
caus
sever
widespread
tissu
infect
among
immunocompromis
patient
aid
transplant
neonat
requir
lengthi
therapeut
regimen
lead
drugresist
toxic
hcmv
lead
caus
morbid
mortal
among
transplant
recipi
result
multiorgan
hcmv
diseas
hsct
sot
transplant
highest
risk
dr
hcmv
seroposit
donor
seroneg
recipi
follow
dr
dr
incid
congenit
cytomegaloviru
ccmv
infect
birth
common
congenit
infect
major
babi
ccmv
infect
clinic
find
birth
asymptomat
infect
remain
born
clinic
appar
symptomat
infect
symptomat
infant
die
newborn
period
symptomat
ccmv
diseas
manifest
rang
mild
nonspecif
find
multipl
organ
system
involv
particular
damag
reticuloendotheli
central
nervou
system
symptomat
asymptomat
ccmv
babi
develop
hear
loss
antivir
approach
either
drug
vaccin
imped
limit
viru
replic
prevent
limit
establish
latenc
reactiv
latenc
reduc
recurr
diseas
thu
diminish
horizont
vertic
transmiss
ideal
vivo
model
use
analysi
antivir
vaccin
mimic
aspect
human
diseas
acut
infect
latenc
viral
pathogenesi
discuss
approv
antiherpesviru
drug
target
well
agent
investig
tabl
though
new
target
includ
cellular
target
may
develop
britt
prichard
treatment
ganciclovir
discov
almost
year
ago
remain
first
line
therapi
although
associ
dose
limit
toxic
resist
second
line
therapi
cidofovir
foscarnet
associ
nephropathi
earli
limit
antivir
intervent
intraven
iv
ganciclovir
oral
valganciclovir
newborn
demonstr
neural
damag
degre
hear
loss
reduc
kimberlin
et
al
kimberlin
et
al
kimberlin
et
al
new
antihcmv
drug
without
toxic
side
effect
need
differ
model
hcmv
infect
develop
tabl
includ
viru
abl
cross
placenta
result
hear
loss
newborn
thu
mimick
human
ccmv
infect
hear
loss
assess
auditoryevok
brainstem
respons
abr
measur
brainstem
respons
auditori
stimuli
model
use
evalu
antihcmv
drug
potenti
transplant
patient
ccmv
rhonda
cardin
also
present
model
hcmv
latenc
myeloid
lineag
cell
main
site
hcmv
latenc
progenitor
cell
myeloid
lineag
cell
deriv
sinclair
reev
isol
cultur
primari
cell
vitro
enabl
reactiv
viru
sort
cell
differenti
latent
infect
primari
myeloid
cell
dendrit
cell
macrophag
result
reactiv
latent
viru
wherea
primari
lytic
infect
reactiv
character
regul
cascad
express
viral
gene
latent
infect
associ
much
restrict
viral
transcript
program
small
number
viral
gene
express
murin
model
vivo
antibodi
deplet
cell
lead
reactiv
mcmv
altern
modul
cell
specif
regulatori
lymphocyt
treg
deplet
decreas
mcmv
latenc
tissu
wherea
offlabel
offlabel
offlabel
hcmv
choic
approv
approv
approv
b
offlabel
offlabel
offlabel
offlabel
offlabel
offlabel
offlabel
offlabel
offlabel
hshv
offlabel
offlabel
offlabel
drug
target
b
approv
prophylaxi
investig
antihcmv
drug
step
inhibit
target
reactiv
viru
salivari
gland
sever
challeng
develop
new
hcmv
therapi
clinic
viral
isol
need
test
addit
primari
cell
type
reinfect
multipl
hcmv
strain
immunocompet
immunocompromis
host
need
consid
studi
rather
complex
vivo
model
infect
mcmv
gpcmv
rhcmv
hcmv
tissu
implant
scid
mice
perform
safeti
evalu
immunocompromis
set
chronic
hcmvassoci
diseas
also
import
consid
candid
combin
therapi
instanc
ganciclovir
letermovir
therapi
hcmv
infect
letermovir
acyclovir
longerterm
prophylaxi
maribavir
could
also
consid
combinatori
antihcmv
therapi
conclus
biolog
hcmv
complex
includ
infect
multipl
hcmv
strain
latenc
reactiv
infect
multipl
cell
type
tissu
diseas
associ
immunosuppress
immunocompet
individu
need
relev
anim
model
reflect
variou
aspect
hcmv
diseas
evalu
antivir
target
hcmv
replic
latenc
lead
continu
discoveri
new
inhibitor
hcmv
novel
molecular
target
combat
hcmv
infect
tim
block
discuss
global
distribut
million
hbv
surfac
ag
posit
peopl
overlap
hepatocellular
carcinoma
hcc
hcc
account
million
death
annual
worldwid
larg
region
variat
exceedingli
high
hcc
mortal
rate
eastsoutheast
asia
sever
area
africa
elserag
rudolph
chronic
hepat
b
due
persist
coval
close
circular
dna
cccdna
hbv
abil
evad
immun
system
consid
major
caus
hcc
two
class
antivir
agent
approv
chronic
hepat
b
interferon
ifn
seven
nucleosidetid
analogu
ie
lamivudin
adefovir
entecavir
peginf
telbivudin
tenofovir
disoproxil
fumar
tdf
taf
tenofovir
alafenamid
analogu
directact
antivir
daa
competit
inhibit
viral
revers
transcriptas
health
record
adult
particip
diagnos
chronic
hbv
infect
chronic
hepat
cohort
studi
show
antivir
treatment
lead
decreas
viral
load
lower
risk
hcc
gordon
et
al
current
antivir
therapi
effect
reduc
viral
replic
decreas
complic
result
chronic
hbv
infect
howev
impact
cccdna
reservoir
thu
cur
unmet
need
new
hbv
treatment
suppress
hbsag
main
goal
new
antihbv
treatment
reduc
elimin
clinic
consequ
chronic
hepat
b
ie
sustain
loss
hbsag
without
develop
hepat
b
surfac
antibodi
antihb
without
need
ongo
therapi
sever
surrog
endpoint
includ
elimin
detect
viremia
normal
circul
level
liver
deriv
enzym
alt
ast
reduct
hb
antigenemia
sustain
drug
benefici
antivir
effect
use
finit
studi
demonstr
potenti
hbsag
loss
sustain
virolog
respons
noncirrhot
hbeagneg
patient
stop
longterm
tdf
therapi
berg
et
al
hbv
life
cycl
present
variou
target
intervent
tim
block
discuss
current
hbv
therapeut
develop
landscap
grow
number
drug
clinic
develop
tabl
experiment
therapi
manag
chronic
hepat
b
pipelin
sever
candid
phase
iii
high
expect
new
hbv
agent
target
specif
viral
gene
product
daa
host
target
indirectact
antivir
agent
iaaa
understand
hbv
entri
process
led
develop
inhibitor
de
novo
hepatocyt
infect
process
requir
coordin
attach
heparan
sulfat
proteoglycan
lowaffin
receptor
follow
highaffin
bind
sodium
taurochol
cotransport
polypeptid
ntcp
myrcludex
b
myrb
myristoyl
peptid
bind
ntcp
inhibit
hbv
entri
strategi
clinic
valid
also
antihdv
effect
stop
replic
cycl
start
howev
current
hbv
ntcp
entri
inhibitor
could
interfer
bile
acid
uptak
hbv
bile
acid
interact
ntcp
site
entri
inhibitor
also
unabl
affect
establish
infect
sever
program
assembl
blumbergarbutu
novarti
novira
roch
sunshin
focu
disrupt
interfer
nucleocapsid
assembl
disassembl
via
small
molecular
core
protein
alloster
modul
cpam
cpam
target
multipl
essenti
viral
function
clinic
valid
escap
mutant
rare
class
cpam
compris
heteroaryldihydropyrimidin
hap
bay
lead
aberr
core
protein
aggreg
subsequ
degrad
class
ii
cpam
encompass
sulfamoylbenzamid
sba
phenylpropenamid
ppa
repres
induc
format
morpholog
normal
empti
capsid
distinct
quaternari
tertiari
structur
chang
prevent
viral
dna
replic
hap
sba
ppa
also
induc
disassembl
nucleocapsid
virion
doublestrand
dnacontain
cytoplasm
progeni
nucleocapsid
thu
interf
cccdna
biosynthesi
de
novo
infect
intracellular
amplif
pathway
guo
et
al
blumberg
institut
arbutu
contravir
replicor
develop
inhibitor
hbv
ag
caus
degrad
hb
rna
ttp
sag
bsbi
sag
sag
preclin
data
sirna
mous
model
demonstr
hbv
dna
reduct
mgkg
clinic
data
ongo
phase
studi
formerli
arohbv
subcutan
administ
rna
interfer
rnai
therapeut
candid
encourag
afford
durabl
reduct
hbsag
patient
achiev
greaterthan
equal
iuml
hbsag
reduct
hbeag
serum
hbv
dna
combinatori
rnai
vaccin
therapi
chronic
hepat
b
achiev
longterm
function
cure
preclin
mous
model
via
induct
virusspecif
cell
respons
hbsag
mrna
degrad
induc
dihydroquinolizinon
compound
develop
roch
depend
hbv
posttranscript
regulatori
element
zhou
et
al
mediat
hbv
rna
reduct
result
acceler
nuclear
viral
rna
degrad
rather
inhibit
transcript
initi
hbv
mrna
biogenesi
may
thu
subvert
normal
cell
mrna
degrad
machineri
also
grow
interest
target
cccdna
program
ongo
gilead
arbutu
assembl
blumberg
fox
chase
duke
rockefel
iaaa
includ
nonimmunomodul
immun
modul
program
akshaya
arbutusblumberg
bm
dynavax
gilead
scienc
heptcel
inovio
roch
springbank
tomegvax
among
nonimmunomodul
agent
develop
tim
block
discuss
gs
histon
lysin
demethylas
inhibitor
innat
host
activ
springbank
put
rigist
act
small
molecul
inarigivir
tlr
agonist
vesatolimod
checkpoint
inhibitor
nivolumab
combin
therapi
investig
purpos
achiev
better
ag
suppress
rather
repress
resist
repress
viremia
antigenemia
two
complementari
daa
could
suffic
larg
percentag
infect
peopl
immun
modul
could
use
antigen
control
enhanc
host
immun
mediat
antivir
respons
current
regimen
result
hb
loss
sustain
drug
benefit
introduct
new
drug
combin
therapi
propos
step
clinic
benefit
better
dna
suppress
superior
sag
loss
enhanc
sabt
cell
function
gain
session
sever
outstand
talk
three
distinct
topic
first
topic
within
symposium
focus
enterovirus
first
talk
bart
tarbet
utah
state
univers
logan
ut
usa
describ
develop
mous
model
neurolog
diseas
associ
infect
enteroviru
use
within
model
interferon
alphagamma
knockout
employ
immun
globulin
control
second
talk
jun
wang
univers
arizona
tucson
az
usa
explor
viral
proteas
enteroviru
potenti
target
antivir
therapi
telapravir
hcv
proteas
inhibitor
demonstr
activ
enteroviru
resist
develop
studi
confirm
proteas
target
second
topic
within
symposium
dealt
model
treat
herp
famili
virus
first
talk
megan
lloyd
suni
upstat
univers
syracus
ny
usa
describ
develop
skin
tissu
model
test
antihcmv
compound
system
done
concurr
organ
cultur
system
measur
effect
said
antivir
compound
second
talk
lui
schang
cornel
univers
ithaca
ny
usa
describ
work
identifi
common
unrel
virus
mean
develop
small
molecul
inhibitor
would
broadspectrum
antivir
activ
toward
end
glycan
bind
influenza
viru
inhibit
bind
digalloyl
ester
describ
final
herpesviru
talk
leor
weinberg
gladston
institut
sand
francisco
ca
usa
describ
disrupt
mean
produc
virusinfect
cell
toxic
key
protein
necessari
herp
viral
replic
selfregul
loss
control
product
protein
lead
cytotox
consequ
within
virusinfect
cell
final
topic
focus
deliveri
immunogen
antigen
influenza
infect
cell
link
zanamivir
virusspecif
neuraminidas
inhibitor
present
xin
liu
purdu
univers
west
lafayett
usa
demonstr
immun
system
better
direct
combat
infect
link
highli
specif
antigen
drug
design
inhibit
virusspecif
protein
interact
demonstr
reduct
infect
compar
administr
zanamivir
alon
session
includ
nine
short
talk
discuss
new
antivir
approach
emerg
viral
pathogen
brian
gowen
utah
state
univers
logan
ut
usa
present
vitro
vivo
activ
excit
new
arenaviru
fusion
inhibitor
develop
arisan
therapeut
five
new
world
arenavirus
nwa
caus
lifethreaten
viral
hemorrhag
fever
america
other
lassa
old
world
support
therapi
ribavirin
immun
plasma
junin
viru
virus
consid
high
prioriti
pathogen
niaid
cdc
envelop
glycoprotein
gpc
mediat
arenaviru
entri
process
phdepend
fusion
endosom
membran
brian
gowen
discuss
antivir
activ
tacarib
viru
tcrv
novel
fusion
inhibitor
preclin
develop
tcrv
close
relat
junin
machupo
virus
pathogen
nwa
doserespons
analys
show
highli
activ
tcrv
subnm
potenc
select
index
si
cc
achiev
highest
concentr
nm
compound
halflif
mice
h
allow
oncedaili
dose
clinic
advers
effect
observ
mgkg
highest
dose
test
mgkg
treatment
start
prophylact
h
infect
protect
mortal
surviv
day
vs
placebo
treat
anim
weight
loss
viremia
liver
spleen
titr
order
magnitud
lower
treat
anim
therapeut
treatment
could
start
day
post
infect
dpi
still
achiev
full
protect
mortal
weight
loss
albeit
viremia
serum
spleen
viral
load
partial
inhibit
treatment
start
dpi
still
protect
mice
lethal
tcrv
challeng
dose
treatment
therefor
effect
start
onset
clinic
sign
requir
support
potenti
clinic
use
tim
sheahan
univers
north
carolina
chapel
hill
nc
usa
present
excit
project
effect
remdesivir
merscov
vitro
vivo
result
collabor
univers
gilead
scienc
vanderbilt
univers
medic
center
coronavirus
cov
natur
predilect
expans
new
host
speci
give
rise
novel
human
diseas
exemplifi
recent
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
mer
caus
sever
respiratori
syndrom
associ
case
death
countri
sinc
zoonot
cov
similar
sar
merscov
circul
anim
reservoir
thu
possibl
novel
cov
may
emerg
futur
current
approv
therapeut
human
cov
remdesivir
rdv
monophosphoramid
prodrug
adenosin
analogu
target
viral
rnadepend
rna
polymeras
rdrp
shown
inhibit
replic
virus
multipl
famili
present
show
rdv
superior
antivir
activ
lpv
vitro
rdv
show
potent
inhibit
merscov
replic
ec
observ
cytotox
human
lung
epitheli
cell
line
ec
valu
lower
lpv
rtv
ec
merscov
iuml
cc
iuml
chang
significantli
iuml
coupl
clinic
relev
lpvrtv
concentr
human
mice
defici
express
gener
model
merscov
lung
viral
load
significantli
reduc
respiratori
function
improv
mice
exhibit
less
weight
loss
prophylact
therapeut
administr
rdv
mgkg
bid
subcutan
compar
vehicl
prophylact
therapeut
combin
lpvrtv
mgkg
rtv
mgkg
qd
po
human
equival
dose
miukg
human
equival
dose
miukg
everi
day
subcutan
slightli
improv
pulmonari
function
prophylact
modest
impact
viral
load
prophylact
treatment
alon
fail
reduc
viral
load
moreov
exacerb
diseas
mike
flint
cdc
atlanta
ga
usa
present
genomewid
screen
use
system
identifi
gene
gnptab
encod
alpha
beta
subunit
transferas
requir
ebola
viru
ebov
replic
valid
screen
confirm
detect
ebov
receptor
hit
confirm
independ
knockout
reexpress
gnptab
activ
follow
cleavag
proteas
particip
traffick
lysosom
hydrolas
gnptab
mutat
result
mucolipidosi
ii
mlii
fibroblast
mlii
patient
far
less
suscept
ebov
cell
healthi
parent
healthi
peopl
gnptab
knockout
result
lower
level
ebov
entri
factor
cathepsin
b
catb
inhibit
proteas
inhibit
ebov
entri
infect
gnptab
potenti
target
antivir
intervent
ebov
also
requir
entri
marburg
nipah
virus
lack
gnptab
activ
result
mucolipidosi
howev
consequ
interf
gnptab
part
ebov
therapi
would
need
care
evalu
colleen
jonsson
univers
tennesse
knoxvil
tn
usa
discuss
famili
inhibitor
venezuelan
eastern
equin
enceph
virus
antivir
approv
treatment
encephalit
infect
produc
virus
alphaviru
epidem
unpredict
occur
sporad
wherea
endem
diseas
common
mostli
undiagnos
thu
difficult
identifi
popul
vaccin
campaign
would
effect
suffici
altern
curtail
outbreak
develop
effect
postexposur
treatment
talk
discuss
evalu
four
analogu
cultur
three
mous
model
best
protect
achiev
mgkgday
twice
daili
day
protect
mice
challeng
veev
trinidad
donkey
trd
lethal
diseas
treatment
start
h
treatment
start
h
postinfect
respect
also
protect
mice
infect
eastern
equin
enceph
viru
dose
mgkgday
day
result
observ
clinic
clinic
chemistri
toxic
interferon
induct
resist
select
cultur
map
mutat
rdrp
critic
mutat
glutamin
gisel
barbosalima
fiocruz
rio
de
janeiro
brazil
present
potenti
repurpos
sofosbuvir
zika
viru
zikv
aim
abl
move
antivir
zikv
promptli
possibl
take
advantag
sofosbuvir
clinic
approv
hepat
c
viru
target
conserv
flaviviru
protein
rdrp
sofosbuvir
triphosph
inhibit
zikv
rdrp
ribavirin
triphosph
sofosbuvir
inhibit
zikv
replic
ip
deriv
neuron
stem
cell
brain
organoid
neonat
mice
model
mgkgday
sofosbuvir
result
lower
level
zikv
rna
approxim
plasma
kidney
brain
spleen
pretreat
mice
infect
confer
modest
protect
lethal
treatment
infect
provid
margin
protect
survivor
sofosbuvir
effect
acut
neuromotor
impair
trigger
zikv
longterm
loss
hippocampaland
amygdaladepend
memori
jessica
spengler
cdc
atlanta
ga
usa
describ
nonrepl
viral
replicon
particl
vrp
base
platform
vaccin
lassa
viru
lasv
crimeancongo
hemorrhag
fever
viru
cchfv
lasv
cchfv
vrp
lack
glycoprotein
gene
therefor
produc
infecti
virion
first
round
replic
although
replic
primarili
infect
cell
result
transcomplement
product
singledos
subcutan
vaccin
ffu
lasv
vrp
protect
guinea
pig
clinic
sign
lethal
challeng
lasv
josiah
strain
vrp
gamma
irradi
result
loss
clinic
protect
lethal
indic
replic
primarili
infect
cell
play
major
role
provid
protect
vaccin
one
day
challeng
postexposur
still
protect
lethal
although
clinic
sign
cchfv
vrp
also
effect
protect
lethal
cchfv
strain
challeng
high
tcid
singl
dose
subcutan
vaccin
prevent
clinic
sign
diseas
anim
wherea
low
dose
tcid
protect
fatal
outcom
critic
cchfv
vrp
confer
heterolog
protect
divers
cchf
strain
leen
delang
rega
institut
medic
research
ku
leuven
belgium
discuss
new
class
chikv
inhibitor
chvbseri
initi
hit
analogu
synthes
activ
potent
origin
hit
ec
valu
reach
low
rang
log
inhibit
replic
show
advers
cellular
effect
compound
inhibit
entri
act
earli
infect
chvbresist
variant
select
less
passag
two
mutat
nonstructur
protein
gene
one
four
mutat
togeth
confer
resist
half
confer
mutat
togeth
mutant
viru
crossresist
madtp
seri
chikv
cap
inhibitor
import
mutat
map
involv
cap
although
function
chikv
avail
chvb
inhibit
methyltransferas
guanylyltransferas
activ
veev
optim
seri
ongo
toward
improv
pk
properti
goal
next
assess
activ
mous
model
randal
lanier
chimerix
durham
nc
usa
present
data
activ
norovirus
despit
high
medic
econom
impact
approxim
death
estim
billion
usd
cost
per
year
indic
vaccin
antivir
norovirus
one
major
challeng
develop
vaccin
drug
high
genet
variabl
howev
shown
earlier
talk
zikv
rdrp
gene
highli
conserv
present
attract
target
drug
discoveri
rdrp
inhibitor
ribonucleosid
analogu
inhibit
nov
rdrp
ic
compet
gtp
pangenotyp
noroviru
activ
ec
mgkg
twice
day
reduc
fecal
mnv
shed
approxim
immunocompet
mice
extend
surviv
lethal
immunocompromis
mous
model
evalu
phase
doubleblind
singledos
escal
clinic
phase
safeti
pharmacokinet
studi
thirtyeight
healthi
adult
divid
cohort
random
receiv
singl
oral
dose
mg
placebo
dose
gener
welltoler
clinic
signific
safeti
concern
identifi
second
part
trial
concentr
activ
form
evalu
h
singl
dose
mg
oral
seven
duoden
biopsi
three
subject
although
detect
sampl
concentr
target
base
vitro
efficaci
conclud
prodrug
optim
formul
like
need
reach
effect
concentr
activ
compound
target
cell
talk
repres
work
chimerix
collabor
univers
cambridg
georgetown
univers
univers
michigan
st
loui
univers
nih
durbad
ojha
niaid
hamilton
mn
usa
present
studi
rottlerin
inhibit
neuron
damag
result
la
cross
viru
lacv
member
california
orthobunyaviru
serogroup
lacv
induc
rare
lifethreaten
neurolog
diseas
children
vaccin
fda
approv
therapi
avail
screen
fda
approv
bioactiv
compound
acquir
nation
center
advanc
transnat
scienc
ncat
identifi
compound
appear
inhibit
lacvinduc
death
human
neuronaltyp
cell
four
select
analys
one
rottlerin
protein
kinas
inhibitor
also
decoupl
mitochondri
respir
oxid
phosphoryl
inhibit
lacvinduc
apoptosi
neuronaltyp
hnsc
cell
primari
murin
neuron
ec
valu
select
index
rottlerin
treatment
reduc
viru
releas
cell
line
suggest
suppress
viru
infect
replic
rottlerin
effect
ad
h
post
infect
rottlerin
inhibit
viru
releas
golgi
independ
mechan
rottlerin
describ
also
pkc
delta
inhibitor
use
intraperiton
intracerebr
rottlerin
inhibit
lacvinduc
diseas
mice
respect
medicin
chemistri
short
session
includ
six
talk
new
chemic
matter
analys
mechan
action
previous
disclos
compound
filip
institut
organ
chemistri
biochemistri
ca
charl
univers
czech
republ
report
develop
new
type
protidelik
prodrug
deliveri
acycl
nucleosid
phosphon
tenofovir
tnf
r
pmpa
select
model
compound
isopropyl
ester
lphenylalanin
suitabl
protect
ltyrosin
deriv
suitabl
mask
group
prepar
tnf
prodrug
evalu
antivir
potenc
comparison
recent
approv
tnf
prodrug
tenofovir
alafenamid
fumar
taf
regard
activ
cell
potent
deriv
mixtur
epim
almost
one
order
magnitud
potent
taf
although
higher
cytotox
tfa
select
index
new
prodrug
still
higher
anoth
tnf
prodrug
singl
epim
isol
use
chiral
hplc
exhibit
potenc
taf
hbv
cell
observ
cytotox
thu
higher
select
index
favipiravir
import
antiinfluenza
agent
requir
intracellular
multistep
metabol
convers
ribonucleosid
triphosph
rtp
exert
antivir
activ
johanna
hucht
univers
hamburg
germani
present
parallel
studi
nonfluorin
analogu
use
three
differ
rna
virus
influenza
punta
toro
variou
cell
exhibit
higher
antivir
potenc
mdck
cell
less
activ
vero
cell
trend
also
reflect
observ
cell
linedepend
propos
indic
superior
antivir
properti
unlik
observ
main
metabolit
vero
cell
convers
rmp
rdp
suggest
bottleneck
limit
antivir
potenc
nora
constanz
fohrmann
univers
hamburg
germani
inform
audienc
discoveri
develop
potent
antivir
agent
bunyavirus
negativesens
singlestrand
rna
virus
highthroughput
screen
toscana
viru
infect
vero
cell
subsequ
structur
modif
hit
led
identif
anthranil
acid
base
inhibitor
potent
variou
rna
virus
ec
valu
low
singledigit
nanomolar
rang
dihydroorot
dehydrogenas
dhodh
identifi
fulli
valid
use
enzym
assay
xray
cocryst
structur
target
intrins
low
metabol
stabil
compound
due
hydrolysi
amid
bond
hepat
microsom
improv
replac
labil
amid
group
stabl
carbam
moieti
ge
meng
fudan
univers
shanghai
china
report
develop
novel
seri
nonnucleosid
revers
transcriptas
inhibitor
nnrti
base
diarylbenzopyrimidin
dabp
scaffold
bear
phenyl
motif
potent
analogu
exhibit
singledigit
nanomolar
activ
wild
type
wt
sever
drugresist
mutant
ec
valu
nm
wt
nm
nm
nm
nm
molecular
dock
sar
studi
provid
insight
interact
dabp
activ
bind
pocket
rt
nucleosid
nucleotid
analogu
drug
repres
import
class
antivir
agent
nucleobas
ribos
moieti
gener
modifi
kalyan
da
rega
institut
medic
research
ku
leuven
belgium
describ
anoth
approach
triphosph
tp
substitut
smaller
chelat
group
eg
phosphon
mimic
tp
moieti
addit
ntp
dntp
mimic
synthes
conjug
damp
tenofovir
varieti
amino
acid
name
lor
dglutam
histidin
methionin
arginin
crystal
structur
reveal
conserv
mode
bind
nucleotid
moieti
wherea
differ
aminoacid
substitut
interact
bind
pocket
differ
result
suggest
potenti
improv
targetspecif
ntpdntp
analogu
introduc
addit
substitut
beyond
tp
substat
proteas
play
essenti
role
flaviviru
replic
therefor
consid
ideal
antivir
drug
target
especi
treatment
dengu
denv
zika
viru
zikv
infect
dahai
luo
nanyang
technolog
univers
singapor
present
highresolut
cocryst
structur
proteas
zikv
bzipro
peptidomimet
inhibitor
observ
bind
mode
interact
inhibitor
within
bzipro
activ
site
result
subsequ
structureact
relationship
studi
lead
design
effect
cyclic
peptidomimet
analogu
proteas
inhibitor
improv
potenc
bioavail
session
includ
seven
talk
center
hepat
b
viru
hiv
clinic
analys
antivir
activ
drug
resist
virus
jinhong
chang
baruch
blumberg
institut
doylestown
pa
usa
present
identif
new
small
molecul
human
sting
agonist
bromon
benzo
bnbc
identifi
ht
screen
compound
bnbc
activ
humanst
depend
cytokin
respons
primari
human
fibroblast
cell
pretreat
cell
bnbc
establish
antivir
state
flavivirus
furthermor
bnbc
also
induc
robust
type
iii
interferon
domin
cytokin
respons
pbmc
pbmcderiv
macrophag
dendrit
cell
promot
dendrit
cell
matur
importantli
bnbc
also
inhibit
cccdna
transcript
viral
replic
hbvinfect
cell
overexpress
ntcp
work
provid
evid
support
develop
sting
agonist
treat
viral
infect
context
dysfunct
immun
respons
hbv
follow
publish
work
show
ligand
effici
amongst
tlr
agonist
directli
inhibit
hbv
replic
infect
hepatocyt
vitro
david
durantel
inserm
lyon
fr
updat
progress
term
preclin
develop
context
immunetherapeut
strategi
report
improv
efficaci
polylacticacid
pla
vitro
vivo
aavhbv
transduc
mice
vivo
far
effici
inhibit
hbv
negativ
viremia
signific
decreas
viral
episom
liver
henc
data
demonstr
potenti
innat
immun
stimul
vivo
antihbv
agent
provid
liver
deliveri
optim
junjun
cheng
baruch
blumberg
institut
doylestown
pa
usa
describ
lossoffunct
genet
screen
individu
ifnstimul
gene
allow
identif
gene
significantli
increas
viral
rna
level
without
alter
cccdna
level
mechanist
studi
pml
show
three
cellular
protein
recruit
cccdna
minichromosom
induc
histon
modif
partial
mimick
one
induc
thu
mediat
least
part
suppress
effect
hepadnavir
cccdna
transcript
tiffani
edward
saint
loui
univers
saint
loui
mo
usa
present
character
hbv
rnase
h
inhibitor
identifi
screen
around
compound
led
identif
inhibitor
classifi
four
chemotyp
compound
shown
select
hbv
rnase
h
versu
human
rnase
growth
bacteri
pathogen
kinet
studi
show
activesit
chelat
compound
differ
chemotyp
noncompetit
inhibitor
other
mixedtyp
inhibitor
cole
schonhof
simon
fraser
univers
burnabi
bc
canada
report
investig
novel
tat
inhibitor
prolat
agent
pla
approach
suppress
express
hiv
reservoir
screen
compound
highthroughput
microscopi
identifi
tatdepend
transcript
inhibitor
lead
hit
two
compound
differ
mode
action
suppress
hiv
latenc
revers
jlat
cell
cell
line
model
hiv
latenc
one
shown
inhibit
activ
cyclindepend
kinas
compon
host
ptefb
complex
requir
tatmedi
transcript
compound
use
probe
mechan
hiv
transcript
inform
ongo
blockandlock
strategi
perman
silenc
latent
hiv
reservoir
peopl
live
hivaid
hanna
schalkwijk
ku
leuven
leuven
belgium
report
case
studi
infect
hematopoiet
stem
cell
transplant
patient
treat
consecut
acyclovir
foscarnet
cidofovir
fourmonth
period
five
viral
isol
obtain
isol
show
popul
heterogen
variant
genotyp
two
isol
demonstr
presenc
mutat
thymidin
kinas
tk
result
acyclovir
resist
isol
present
differ
mutat
tk
dna
polymeras
led
resist
acyclovir
foscarnet
tk
novel
polymorph
affect
drug
suscept
two
isol
obtain
day
differ
bodi
site
show
differ
heterogen
frequenc
viral
variant
studi
demonstr
type
drugresist
multipl
time
point
multipl
bodi
site
use
approach
adjust
antivir
therapi
elain
thoma
revir
ltd
stevenag
uk
describ
studi
sisunatovir
inhibitor
respiratori
syncyti
viru
rsv
rsv
major
caus
lower
respiratori
tract
infect
especi
infant
drug
avail
phase
studi
show
sisunatovir
safe
phase
rsv
challeng
studi
show
sisunatovir
abl
reduc
viral
load
diseas
sever
compar
placebo
group
vitro
character
sisunatovir
resist
show
target
viral
f
protein
fprotein
gene
select
mutat
increas
ec
valu
howev
mutant
viru
reduc
vitro
fit
inabl
compet
wt
rsv
two
rsv
f
protein
variant
detect
sisunatovir
treat
subject
mutat
result
emerg
clinic
resist
customari
icar
includ
poster
award
shot
gun
present
author
select
poster
continu
last
year
success
icar
held
second
pechakucha
competit
well
winner
chu
famili
foundat
award
also
announc
meet
shotgun
present
cochair
justin
juland
ila
nimgaonkar
pechakucha
event
winner
